2026 Practice-Changing Updates in Genitourinary Cancer

New Evidence, New Standards, & Multidisciplinary Decisions

WEDNESDAY, NOVEMBER 18, 2026 | PHILADELPHIA MARRIOTT OLD CITY | 5:30–9:00 PM




Fox Chase Cancer Center
Temple Health

Program Directors



Fern M. Anari, MD

Associate Professor,
Department of Hematology/Oncology
Fox Chase Cancer Center



Andres F. Correa, MD

Associate Professor & Director of Research,
Department of Urology
Society of Urologic Oncology Fellowship Program Director
Fox Chase Cancer Center
Fox Chase – Temple Urologic Institute Provider

Scan to access **interactive agenda** with links to speaker profiles and genitourinary cancer physician resources.

Educational Objectives:

Upon completion of this activity, participants should be able to:

- Select appropriate treatment intensification strategies for metastatic prostate cancer, incorporating disease volume, patient fitness, biomarkers, and emerging PSMA-directed approaches.
- Evaluate perioperative treatment strategies for high-risk localized prostate cancer, incorporating new evidence from the PROTEUS trial and implications for surgical management.
- Integrate contemporary perioperative systemic therapies into the management of muscle-invasive bladder cancer, including the emerging role of ctDNA/MRD in treatment decision-making.
- Apply updated risk stratification and treatment approaches for non-muscle-invasive bladder cancer (NMIBC) when selecting bladder-sparing therapies, radical cystectomy, or clinical trials.
- Evaluate and sequence contemporary therapies for renal cell carcinoma, including new combinations in adjuvant and advanced disease settings.
- Identify evolving applications of radiation therapy in genitourinary malignancies, including integration with systemic and surgical treatment strategies.
- Apply a multidisciplinary, evidence-based approach to treatment selection across prostate, bladder, and kidney cancers.

INTENDED AUDIENCE

The program is designed for medical, surgical, and radiation oncologists; urologists; radiologists; primary care physicians; fellows; residents; nurses; and other healthcare providers.

ACCREDITATION STATEMENT

The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of ***2 AMA PRA Category 1 Credits™***. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.

INQUIRIES

Lucía Tono, PhD, MEd Lucia.Tono-Ramirez@tuhs.temple.edu

Agenda

5:30–6:45 PM — **Check-in & Reception**

6:30 PM — **Dinner Buffet Opens**

7:00–7:10 PM — **Welcome and Overview:**

What Changed in GU Oncology in 2026?
Fern M. Anari, MD and **Andres F. Correa, MD**

7:10–7:30 PM — **Metastatic Prostate Cancer: Treatment Intensification, Biomarkers and New Therapeutic Strategies**



Daniel M. Geynisman, MD
Chief, Division of Genitourinary Medical Oncology
Professor, Department of Hematology/Oncology
Vice Chair, Quality Improvement Program
Fox Chase Cancer Center

7:30–7:50 PM — **Muscle-Invasive Bladder Cancer: Perioperative Therapy and the Evolving Treatment Algorithm**




Pooja Ghatalia, MD
Associate Professor, Department of Hematology/Oncology
Collaborating Member, Cancer Epigenetics
Nuclear Dynamics and Cancer Research Program
Fox Chase Cancer Center

7:50–8:10 PM — **Renal Cell Carcinoma: Emerging Evidence and Treatment Sequencing**



Gregory Hemenway, MD
Assistant Professor, Department of Hematology/Oncology
Fox Chase Cancer Center

8:10–8:30 PM — **Urologic Oncology Update: New Approaches in Prostate and Bladder Cancer**



Andres F. Correa, MD
Associate Professor & Director of Research,
Department of Urology
Society of Urologic Oncology Fellowship Program Director
Fox Chase Cancer Center
Fox Chase – Temple Urologic Institute Provider

8:30–8:45 PM — **Localized Prostate Cancer: Biomarker Integration and Selective Radiation Volume**



Hilario Yankey, MD
Assistant Professor, Department of Radiation Oncology
Fox Chase Cancer Center

8:45–9:00 PM — **Multidisciplinary Case Challenge: Putting the 2026 Evidence into Practice**

MODERATORS:
Fern M. Anari, MD and **Andres F. Correa, MD**

PANELISTS:
Daniel M. Geynisman, MD; Pooja Ghatalia, MD; Gregory Hemenway, MD; Hilario Yankey, MD

9:00 PM — **Closing Remarks**

EXHIBITORS

Presenting

Exelixis

Silver

AstraZeneca
Bayer
Johnson & Johnson
Novartis
Pfizer

Bronze

Astellas
Bristol Myers Squibb
Eisai
Ferring Pharmaceuticals
Foundation Medicine
Guardant Health
ImmunityBio
Merck
Natera
Photocure
Sumitomo Pharma America
Telix Pharmaceuticals
UroGen Pharma
Veracyte

Fox Chase Cancer Center
Temple Health

FoxChase.org

Non-discrimination notice: It is the policy of Fox Chase Cancer Center and Temple University Hospital, Inc., that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

© Fox Chase Cancer Center. All rights reserved. 11/26